Growth Metrics

Nautilus Biotechnology (NAUT) Change in Accured Expenses (2020 - 2026)

Nautilus Biotechnology has reported Change in Accured Expenses over the past 7 years, most recently at $128000.0 for Q1 2026.

  • Quarterly results put Change in Accured Expenses at $128000.0 for Q1 2026, down 75.62% from a year ago — trailing twelve months through Mar 2026 was $232000.0 (up 138.41% YoY), and the annual figure for FY2025 was $629000.0, up 145.03%.
  • Change in Accured Expenses reached $128000.0 in Q1 2026 per NAUT's latest filing, up from -$703000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $942000.0 in Q3 2025 and bottomed at -$703000.0 in Q4 2025.
  • Median Change in Accured Expenses over the past 5 years was -$135000.0 (2025), compared with a mean of $10941.2.
  • The largest annual shift saw Change in Accured Expenses crashed 512.31% in 2024 before it surged 4195.65% in 2025.
  • Over 5 years, Change in Accured Expenses stood at -$451000.0 in 2022, then increased by 24.61% to -$340000.0 in 2023, then plummeted by 96.47% to -$668000.0 in 2024, then fell by 5.24% to -$703000.0 in 2025, then skyrocketed by 118.21% to $128000.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for NAUT at $128000.0 in Q1 2026, -$703000.0 in Q4 2025, and $942000.0 in Q3 2025.